All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 2 April 2019, Nancy Bartlett from Washington University School of Medicine, St Louis, MO, USA and colleagues, published in the Journal of Clinical Oncology results from a phase III clinical trial that compared the efficacy of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for diffuse large B-cell lymphoma (DLBCL).
In this randomized, Alliance/CALGB 50303 study (NCT00118209), the efficacy and safety of DA-EPOCH-R and R-CHOP were compared as frontline treatment for patients with DLBCL. The primary endpoint was progression-free survival (PFS), while secondary endpoints included response rates, overall survival (OS), and safety.
|
DA-EPOCH-R arm |
R-CHOP arm |
---|---|---|
Eastern Cooperative Oncology Group (ECOG) performance status: |
|
|
ECOG 0 |
46.9% |
40.6% |
ECOG 1 |
39.8% |
47.8% |
ECOG 2 |
13.3% |
11.6% |
Missing |
n = 0 |
n = 1 |
International Prognostic Index (IPI) risk groups: |
|
|
Low |
25.1% |
26.6% |
Low-intermediate |
35.3% |
38.6% |
High-intermediate |
26.0% |
24.9% |
High |
13.6% |
10.0% |
Missing |
n = 6 |
n = 9 |
|
DA-EPOCH-R arm |
R-CHOP arm |
Full cohort |
---|---|---|---|
Two-year PFS rate |
78.9% |
75.5% |
77.1% (95% CI, 73.5−81) |
Five-year PFS rate |
68.0% |
66.0% |
67.1% (95% CI, 62.8−71.6) |
Five-year OS rate |
77.5% |
78.5% |
78.0% (95% CI, 74.3−81.9) |
Overall response rate |
86.7% |
88.0% |
- |
Complete response (CR) and unconfirmed CR (CRu) rate |
58.5% |
59.6% |
- |
|
P = 0.67 |
- |
DA-EPOCH-R was associated with greater toxicity and did not improve PFS, OS or response rate when compared to R-CHOP, as frontline treatment in naïve patients with DLBCL or PMBCL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox